Poolbeg Pharma PLC (LON:POLB – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 6.96 ($0.09) and last traded at GBX 7.14 ($0.09), with a volume of 463643 shares. The stock had previously closed at GBX 7.20 ($0.09).
Poolbeg Pharma Trading Down 0.8 %
The company has a market capitalization of £35.70 million, a PE ratio of -714.00 and a beta of 2.11. The stock has a fifty day simple moving average of GBX 7.96 and a 200-day simple moving average of GBX 10.79.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Stories
- Five stocks we like better than Poolbeg Pharma
- What is Insider Trading? What You Can Learn from Insider Trading
- The Great CPU Race: AMD and Intel Battle for Dominance
- Best Stocks Under $5.00
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Where Do I Find 52-Week Highs and Lows?
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
